Anti-Tau Agent Bepranemab Slows Tau Accumulation in Phase 2 TOGETHER Trial
Written by
Neurology Live
Published
0
comments
0
min
UCB's bepranemab shows promise in slowing tau accumulation in early Alzheimer disease, marking an advancement in tau-targeted therapies.